Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteasome inhibitors and <scp>IM</scp>iDs can overcome some high‐risk cytogenetics in multiple myeloma but not gain 1q21

17 Mar 2015

Abstract excerpt

Chromosomal aberrations have significant prognostic importance in multiple myeloma (MM). However, proteasome inhibitors (PI) and IMiDs may partly overcome the poor prognostic impact of some of them. In this study, we investigated a population-based consecutive cohort newly diagnosed patients with MM admitted during a defined time period to hospitals in Denmark, Norway, and Sweden. The impact of treatment modality...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Multiple Myeloma Research and Treatments
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25779478
DOI: 10.1111/ejh.12546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteasome inhibitors and <scp>IM</scp>iDs can overcome some high‐risk cytogenetics in multiple myeloma but not gain 1q21PMID 25779478Read ↗

Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma PatientsSemantic proximity Read ↗

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic valueSemantic proximity Read ↗

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalitiesSemantic proximity Read ↗

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic eventSemantic proximity Read ↗

Gain/Amplification of Chromosome Arm 1q21 in Multiple MyelomaSemantic proximity Read ↗

Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose ChemotherapySemantic proximity Read ↗

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.Semantic proximity Read ↗

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic TargetsSemantic proximity Read ↗

Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implicationsSemantic proximity Read ↗

Chromosome 1q21 abnormalities in multiple myelomaSemantic proximity Read ↗

Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literatureSemantic proximity Read ↗

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.